Evidence map›Paper›PMID 38760043›Full record

ArticleBMJ open2024

Improving the care of children with GENetic Rare disease: Observational Cohort study (GenROC)-a study protocol.

Karen Jaqueline Low, Amy Watford, Peter Blair, Ian Nabney, John Powell, Sarah L Wynn, Julia Foreman, Helen Firth, Jenny Ingram

Abstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Identifying the Impacts, Obstacles and Information Barriers for Parents of Children Living With Genetic Neurodevelopmental Disorders: A Qualitative Study.Health expectations : an international journal of public participation in health care and health policy · 2025
    Observational
  6. Genetic investigations in cerebral palsy.Developmental medicine and child neurology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Karen Jaqueline LowCentre for Academic Child Health, University of Bristol, Bristol, UK karen.low@bristol.ac.uk.ORCID 0000-0002-4975-9363
Amy WatfordDepartment of Clinical Genetics, University Hospitals Bristol and Weston NHS Trust, Bristol, UK.
Peter BlairCentre for Academic Child Health, University of Bristol, Bristol, UK.
Ian NabneySchool of Computer Science, Electrical and Electronic Engineering and Engineering Maths, University of Bristol, Bristol, UK.
John PowellNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Sarah L WynnUnique Rare Chromosome Disorder Support Group, Oxted, UK.
Julia ForemanEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, UK.
Helen FirthClinical Genetics, Cambridge University Hospitals, Cambridge, UK.
Jenny IngramCentre for Academic Child Health, School of Social & Community Medicine, Bristol University, Bristol, UK.ORCID 0000-0003-2366-008X

Funding

Wellcome Trust
6 · The paper itself

Abstract

introductionAround 2000 children are born in the UK per year with a neurodevelopmental genetic syndrome with significantly increased morbidity and mortality. Often little is known about expected growth and phenotypes in these children. Parents have responded by setting up social media groups to generate data themselves. Given the significant clinical evidence gaps, this research will attempt to identify growth patterns, developmental profiles and phenotypes, providing data on long-term medical and educational outcomes. This will guide clinicians when to investigate, monitor or treat symptoms and when to search for additional or alternative diagnoses. METHODS AND ANALYSIS: This is an observational, multicentre cohort study recruiting between March 2023 and February 2026. Children aged 6 months up to 16 years with a pathogenic or likely pathogenic variant in a specified gene will be eligible. Children will be identified through the National Health Service and via self-recruitment. Parents or carers will complete a questionnaire at baseline and again 1 year after recruitment. The named clinician (in most cases a clinical geneticist) will complete a clinical proforma which will provide data from their most recent clinical assessment. Qualitative interviews will be undertaken with a subset of parents partway through the study. Growth and developmental milestone curves will be generated through the DECIPHER website (https://deciphergenomics.org) where 5 or more children have the same genetic syndrome (at least 10 groups expected). ETHICS AND DISSEMINATION: The results will be presented at national and international conferences concerning the care of children with genetic syndromes. Results will also be submitted for peer review and publication.

Indexed as

Rare DiseasesAdolescentChildChild, PreschoolCohort StudiesFemaleGenetic Diseases, InbornHumansInfantMaleMulticenter Studies as TopicNeurodevelopmental DisordersObservational Studies as TopicParentsQuality ImprovementResearch Designcommunity child healthpaediatric clinical genetics & dysmorphologypaediatric neurology

Identifiers

PMID38760043
PMCPMC11103197

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.